Amelia Kelley
Psychiatric/Mental Health · Meridian, MSNPI 1780068056
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,088 of the $38,253 with a category attached, or 78.7%. AbbVie accounts for 89.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $19,088 and has fallen 58.5% since, to $7,926 in 2025. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $96.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Teva Pharmaceuticals USA, Inc.$724
- Otsuka America Pharmaceutical, Inc.$682
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$615
- Lundbeck LLC$377
- Vanda Pharmaceuticals Inc.$367
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$30,08879%
- Travel & lodging$2,1586%
- Food & beverage$5,86315%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 144 | $34,109 |
| Teva Pharmaceuticals USA, Inc. | 33 | $724 |
| Otsuka America Pharmaceutical, Inc. | 56 | $682 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $615 |
| Lundbeck LLC | 20 | $377 |
| Vanda Pharmaceuticals Inc. | 16 | $367 |
| Neurocrine Biosciences, Inc. | 20 | $301 |
| E.r. Squibb & Sons, L.L.C. | 23 | $265 |
| Supernus Pharmaceuticals, Inc. | 14 | $159 |
| Alkermes, Inc. | 7 | $155 |
| Axsome Therapeutics, Inc. | 8 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Indivior Inc. | 5 | $104 |
| Johnson & Johnson | 3 | $45 |
| Tris Pharma Inc | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,253 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 129 | $398,625 |
| Abilify MaintenaAripiprazole | 85 | $238,412 |
| IngrezzaValbenazine Tosylate | 25 | $203,976 |
| VraylarCariprazine Hcl | 102 | $143,818 |
| AustedoDeutetrabenazine | 11 | $121,198 |
| RexultiBrexpiprazole | 57 | $114,942 |
| CaplytaLumateperone Tosylate | 42 | $73,529 |
| TrintellixVortioxetine Hydrobromide | 90 | $57,061 |
| AristadaAripiprazole Lauroxil | 15 | $43,217 |
| PerserisRisperidone | 15 | $43,201 |
| UzedyRisperidone | 13 | $35,742 |
| Lurasidone Hcl | 46 | $15,758 |
| BelsomraSuvorexant | 31 | $13,102 |
| Aripiprazole | 145 | $5,002 |
| Haloperidol Decanoate | 103 | $4,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $45 | $398,625129 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $682 | $353,354142 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $301 | $203,97625 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $724 | $156,94024 claims |
| AbbVieVraylar | $34,109 | $143,818102 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $615 | $73,52942 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $132 | $57,06190 claims |
| Alkermes, Inc.Aristada | $155 | $43,21715 claims |
| Indivior Inc.Perseris | $104 | $43,20115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Meridian
- Hailey StokesMeridian$5K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
- Rose CliffordGautier$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.